Descriptive analysis of Cycle Threshold in patients with hematologic malignancies infected with SARS-COV-2
Introduction: SARS-CoV-2 has caused over 200 million documented infections, more than 4 million deaths, and unprecedented consequences worldwide. The cycle threshold (Ct), the number of amplification cycles required to obtain a product detectable through fluorescence during a quantitative RT-PCR tes...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Inglés |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2023
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/38171 |
| Aporte de: |
| id |
I10-R327-article-38171 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| language |
Inglés |
| format |
Artículo revista |
| topic |
polymerase chain reaction hematologic neoplasms coronavirus infections reacción en cadena de la polimerasa neoplasias hematológicas infecciones por coronavirus reação em cadeia da polimerase neoplasias hematológicas infeccões por coronavirus |
| spellingShingle |
polymerase chain reaction hematologic neoplasms coronavirus infections reacción en cadena de la polimerasa neoplasias hematológicas infecciones por coronavirus reação em cadeia da polimerase neoplasias hematológicas infeccões por coronavirus Santarelli, Ignacio Martín Manzella, Diego Jorge Gallo Vaulet, Lucía Rodríguez Fermepín, Marcelo Fernández, Sofía Isabel Descriptive analysis of Cycle Threshold in patients with hematologic malignancies infected with SARS-COV-2 |
| topic_facet |
polymerase chain reaction hematologic neoplasms coronavirus infections reacción en cadena de la polimerasa neoplasias hematológicas infecciones por coronavirus reação em cadeia da polimerase neoplasias hematológicas infeccões por coronavirus |
| author |
Santarelli, Ignacio Martín Manzella, Diego Jorge Gallo Vaulet, Lucía Rodríguez Fermepín, Marcelo Fernández, Sofía Isabel |
| author_facet |
Santarelli, Ignacio Martín Manzella, Diego Jorge Gallo Vaulet, Lucía Rodríguez Fermepín, Marcelo Fernández, Sofía Isabel |
| author_sort |
Santarelli, Ignacio Martín |
| title |
Descriptive analysis of Cycle Threshold in patients with hematologic malignancies infected with SARS-COV-2 |
| title_short |
Descriptive analysis of Cycle Threshold in patients with hematologic malignancies infected with SARS-COV-2 |
| title_full |
Descriptive analysis of Cycle Threshold in patients with hematologic malignancies infected with SARS-COV-2 |
| title_fullStr |
Descriptive analysis of Cycle Threshold in patients with hematologic malignancies infected with SARS-COV-2 |
| title_full_unstemmed |
Descriptive analysis of Cycle Threshold in patients with hematologic malignancies infected with SARS-COV-2 |
| title_sort |
descriptive analysis of cycle threshold in patients with hematologic malignancies infected with sars-cov-2 |
| description |
Introduction: SARS-CoV-2 has caused over 200 million documented infections, more than 4 million deaths, and unprecedented consequences worldwide. The cycle threshold (Ct), the number of amplification cycles required to obtain a product detectable through fluorescence during a quantitative RT-PCR test, is an indirect measurement of viral load. Patients with hematologic malignancies have an increased risk of death by the SARS-CoV-2. Cases presentation: We conducted a retrospective, observational, descriptive analysis of the Ct obtained from patients with history of hematologic malignancies who tested positive for SARS-CoV-2 in our hospital, from March 3rd, 2020, to August 17th, 2021. We used the mean Ct at diagnosis. 15 adults, with previous diagnosis of lymphomas, acute leukemias and chronic lymphocytic leukemia, were included. 9 of the 15 patients (60 %) developed pneumonia, 6 of them required supplementary oxygen and 5 mechanical ventilation. 5 patients died between 7-86 days from symptom onset. Ct was lower among the group of patients who died (15.5 cycles; SD= 2.28, CI95%= 9.17-21.86) compared with those who survived (20.2 cycles; SD= 8.87, CI95%= 13.9-26.6). Ct was also lower in the pneumonia group (18.2 cycles; SD= 2.28, CI95%= 12.98-23.51) than in the no-pneumonia group (19.3 cycles; SD= 4.11; CI95%= 8.73-29.9). Discussion: Ct was lowest in severe forms of CoViD-19. Further studies with larger populations of patients with hematologic malignancies could establish the validity of Ct as a quantitative laboratory determination as a course-prediction and infectivity tool. |
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2023 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/38171 |
| work_keys_str_mv |
AT santarelliignaciomartin descriptiveanalysisofcyclethresholdinpatientswithhematologicmalignanciesinfectedwithsarscov2 AT manzelladiegojorge descriptiveanalysisofcyclethresholdinpatientswithhematologicmalignanciesinfectedwithsarscov2 AT gallovauletlucia descriptiveanalysisofcyclethresholdinpatientswithhematologicmalignanciesinfectedwithsarscov2 AT rodriguezfermepinmarcelo descriptiveanalysisofcyclethresholdinpatientswithhematologicmalignanciesinfectedwithsarscov2 AT fernandezsofiaisabel descriptiveanalysisofcyclethresholdinpatientswithhematologicmalignanciesinfectedwithsarscov2 AT santarelliignaciomartin analisisdescriptivodelumbraldecicladoenpacientesconneoplasiashematologicasinfectadosporsarscov2 AT manzelladiegojorge analisisdescriptivodelumbraldecicladoenpacientesconneoplasiashematologicasinfectadosporsarscov2 AT gallovauletlucia analisisdescriptivodelumbraldecicladoenpacientesconneoplasiashematologicasinfectadosporsarscov2 AT rodriguezfermepinmarcelo analisisdescriptivodelumbraldecicladoenpacientesconneoplasiashematologicasinfectadosporsarscov2 AT fernandezsofiaisabel analisisdescriptivodelumbraldecicladoenpacientesconneoplasiashematologicasinfectadosporsarscov2 AT santarelliignaciomartin analisedescritivadolimiardeciclismoempacientescomneoplasiashematologicasinfectadascomsarscov2 AT manzelladiegojorge analisedescritivadolimiardeciclismoempacientescomneoplasiashematologicasinfectadascomsarscov2 AT gallovauletlucia analisedescritivadolimiardeciclismoempacientescomneoplasiashematologicasinfectadascomsarscov2 AT rodriguezfermepinmarcelo analisedescritivadolimiardeciclismoempacientescomneoplasiashematologicasinfectadascomsarscov2 AT fernandezsofiaisabel analisedescritivadolimiardeciclismoempacientescomneoplasiashematologicasinfectadascomsarscov2 |
| first_indexed |
2024-09-03T21:03:39Z |
| last_indexed |
2024-09-03T21:03:39Z |
| _version_ |
1809210324108181504 |
| spelling |
I10-R327-article-381712023-07-10T12:03:20Z Descriptive analysis of Cycle Threshold in patients with hematologic malignancies infected with SARS-COV-2 Análisis descriptivo del umbral de ciclado en pacientes con neoplasias hematológicas infectados por SARS-COV-2 Análise descritiva do limiar de ciclismo em pacientes com neoplasias hematológicas infectadas com SARS-CoV-2 Santarelli, Ignacio Martín Manzella, Diego Jorge Gallo Vaulet, Lucía Rodríguez Fermepín, Marcelo Fernández, Sofía Isabel polymerase chain reaction hematologic neoplasms coronavirus infections reacción en cadena de la polimerasa neoplasias hematológicas infecciones por coronavirus reação em cadeia da polimerase neoplasias hematológicas infeccões por coronavirus Introduction: SARS-CoV-2 has caused over 200 million documented infections, more than 4 million deaths, and unprecedented consequences worldwide. The cycle threshold (Ct), the number of amplification cycles required to obtain a product detectable through fluorescence during a quantitative RT-PCR test, is an indirect measurement of viral load. Patients with hematologic malignancies have an increased risk of death by the SARS-CoV-2. Cases presentation: We conducted a retrospective, observational, descriptive analysis of the Ct obtained from patients with history of hematologic malignancies who tested positive for SARS-CoV-2 in our hospital, from March 3rd, 2020, to August 17th, 2021. We used the mean Ct at diagnosis. 15 adults, with previous diagnosis of lymphomas, acute leukemias and chronic lymphocytic leukemia, were included. 9 of the 15 patients (60 %) developed pneumonia, 6 of them required supplementary oxygen and 5 mechanical ventilation. 5 patients died between 7-86 days from symptom onset. Ct was lower among the group of patients who died (15.5 cycles; SD= 2.28, CI95%= 9.17-21.86) compared with those who survived (20.2 cycles; SD= 8.87, CI95%= 13.9-26.6). Ct was also lower in the pneumonia group (18.2 cycles; SD= 2.28, CI95%= 12.98-23.51) than in the no-pneumonia group (19.3 cycles; SD= 4.11; CI95%= 8.73-29.9). Discussion: Ct was lowest in severe forms of CoViD-19. Further studies with larger populations of patients with hematologic malignancies could establish the validity of Ct as a quantitative laboratory determination as a course-prediction and infectivity tool. Introducción: SARS-CoV-2 ha causado más de 200 millones de infecciones documentadas, más de 4 millones de muertes, y consecuencias sin precedentes globalmente. El umbral de ciclado (Ct), número de ciclos de amplificación requerido para obtener un producto detectable durante una prueba cuantitativa de RT-PCR, es una medida indirecta de la carga viral. Los pacientes con enfermedades oncohematológicas tienen mayor riesgo de muerte por SARS-CoV-2. Presentación de casos: Realizamos un estudio observacional, retrospectivo y descriptivo de los valores de Ct obtenidos de pacientes con enfermedades oncohematológicas que resultaron positivos para SARS-CoV-2 en nuestro hospital, desde el 3 de marzo de 2020, hasta el 17 de agosto de 2021. Empleamos el Ct promedio al diagnóstico. Fueron incluidos 15 adultos, con diagnóstico de linfomas, leucemias agudas y leucemia linfocítica crónica. 9 pacientes (60 %) desarrollaron neumonía, 6 requirieron oxígeno suplementario y 5 ventilación mecánica. 5 murieron a los 7-86 días desde el inicio de síntomas. Ct fue menor entre los pacientes que murieron (15.5 ciclos; DS= 2.28, IC95%= 9.17-21.86), comparado con los que sobrevivieron (20.2 ciclos; DS= 8.87, IC95%= 13.9-26.6). La misma tendencia se observó en el grupo de los que desarrollaron neumonía (18.2 ciclos; DS= 2.28, IC95%= 12.98-23.51), comparado con lo que no tuvieron neumonía (19.3 ciclos; DS= 4.11; IC95%= 8.73-29.9). Discusión: El valor de Ct fue más bajo en las formas más graves de CoViD-19. Estudios adicionales con poblaciones mayores de pacientes con enfermedades oncohematológicas podrían establecer la validez de Ct como determinación cuantitativa de laboratorio útil como predictora de evolución e infectividad. Introdução: O SARS-CoV-2 causou mais de 200 milhões de infecções documentadas, mais de 4 milhões de mortes e consequências sem precedentes em todo o mundo. O limiar de ciclagem (Ct), o número de ciclos de amplificação necessários para obter um produto detectável durante um teste quantitativo de RT-PCR, é uma medida indireta da carga viral. Pacientes com doenças oncohematológicas têm maior risco de morte por SARS-CoV-2. Apresentação do caso: Realizamos um estudo observacional, retrospectivo e descritivo dos valores de Ct obtidos de pacientes com doenças oncohematológicas positivos para SARS-CoV-2 em nosso hospital, de 3 de março de 2020 a 17 de agosto de 2021. Usamos o Ct médio no diagnóstico. Quinze adultos diagnosticados com linfomas, leucemia aguda e leucemia linfocítica crônica foram incluídos. 9 pacientes (60%) desenvolveram pneumonia, 6 necessitaram de oxigênio suplementar e 5 ventilação mecânica. 5 morreram dentro de 7-86 dias a partir do início dos sintomas. A Ct foi menor entre os pacientes que morreram (15,5 ciclos; DP= 2,28, IC95%= 9,17-21,86), comparados aos que sobreviveram (20,2 ciclos; DP= 8,87, IC95%= 13,9-26,6). A mesma tendência foi observada no grupo que desenvolveu pneumonia (18,2 ciclos; DP= 2,28; IC95%= 12,98-23,51), em relação aos que não tiveram pneumonia (19,3 ciclos; DP= 4,11; IC95%= 8,73-29,9). Discussão: O valor de Ct foi menor nas formas mais graves de CoViD-19. Estudos adicionais com populações maiores de pacientes com doenças oncohematológicas poderiam estabelecer a validade da Ct como uma determinação laboratorial quantitativa útil como preditor de evolução e infectividade. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2023-03-31 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Text text/html application/pdf https://revistas.unc.edu.ar/index.php/med/article/view/38171 10.31053/1853.0605.v80.n1.38171 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 80 No. 1 (2023); 47-51 Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 80 Núm. 1 (2023); 47-51 Revista da Faculdade de Ciências Médicas de Córdoba; v. 80 n. 1 (2023); 47-51 1853-0605 0014-6722 10.31053/1853.0605.v80.n1 eng https://revistas.unc.edu.ar/index.php/med/article/view/38171/40812 https://revistas.unc.edu.ar/index.php/med/article/view/38171/40949 Derechos de autor 2023 Universidad Nacional de Córdoba http://creativecommons.org/licenses/by-nc/4.0 |